CIP-Fenofibrate for Cholesterol Disorders
Final approval has been granted for CIP-Fenofibrate (Lipofen, Cipher Pharmaceuticals), a novel formulation of the active ingredient fenofibrate, which is used in the treatment of hyperlipidemia. Three dosages were approved: 50, 100 and 150 mg. The 150-mg strength is equivalent to Abbott’s Tricor 160 mg (under fed, not fasting, conditions). The new agent’s absorption is [...]
Read User's Comments